Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial (Q48738063)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

Dafna D. Gladman

13

object named as

Dafna Gladman

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

author name string

Philip Mease

1

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Mark C Genovese

2

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Geoffrey Gladstein

3

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Alan J Kivitz

4

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Christopher Ritchlin

5

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Paul P Tak

6

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Jürgen Wollenhaupt

7

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Orna Bahary

8

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Jean-Claude Becker

9

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Sheila Kelly

10

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Leonard Sigal

11

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Julie Teng

12

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

publication date

1 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

63

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

4

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

939-948

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

Epidemiology of psoriatic arthritis in the population of the United States.

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Treatment recommendations for psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

T cells in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

The clinical utility of inhibiting CD28-mediated costimulation

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned?

1 reference

https://api.crossref.org/works/10.1002%2FART.30176

21 January 2018

Identifiers

10.1002/ART.30176

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 February 2018

http://europepmc.org/abstract/MED/21128258

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48738063&oldid=2208957617"